402 related articles for article (PubMed ID: 37517999)
21. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
22. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
23. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.
Biswas S; Hwang JW; Kirkham PA; Rahman I
Curr Med Chem; 2013; 20(12):1496-530. PubMed ID: 22963552
[TBL] [Abstract][Full Text] [Related]
25. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.
Calzetta L; Matera MG; Rogliani P; Cazzola M
Expert Rev Respir Med; 2018 Aug; 12(8):693-708. PubMed ID: 29972340
[TBL] [Abstract][Full Text] [Related]
26. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Black PN
Cochrane Database Syst Rev; 2010 Feb; (2):CD001287. PubMed ID: 20166060
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
28. Cigarette smoke extract induced exosome release is mediated by depletion of exofacial thiols and can be inhibited by thiol-antioxidants.
Benedikter BJ; Volgers C; van Eijck PH; Wouters EFM; Savelkoul PHM; Reynaert NL; Haenen GRMM; Rohde GGU; Weseler AR; Stassen FRM
Free Radic Biol Med; 2017 Jul; 108():334-344. PubMed ID: 28359953
[TBL] [Abstract][Full Text] [Related]
29. Role of mucolytics in the management of COPD.
Poole PJ
Int J Chron Obstruct Pulmon Dis; 2006; 1(2):123-8. PubMed ID: 18046889
[TBL] [Abstract][Full Text] [Related]
30. Antioxidant therapeutic targets in COPD.
Rahman I; Kilty I
Curr Drug Targets; 2006 Jun; 7(6):707-20. PubMed ID: 16787173
[TBL] [Abstract][Full Text] [Related]
31. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
Sadowska AM
Ther Adv Respir Dis; 2012 Jun; 6(3):127-35. PubMed ID: 22361928
[TBL] [Abstract][Full Text] [Related]
32. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.
Postma DS; Roche N; Colice G; Israel E; Martin RJ; van Aalderen WM; Grigg J; Burden A; Hillyer EV; von Ziegenweidt J; Gopalan G; Price D
Int J Chron Obstruct Pulmon Dis; 2014; 9():1163-86. PubMed ID: 25378918
[TBL] [Abstract][Full Text] [Related]
33. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.
Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
Trends Pharmacol Sci; 2019 Jul; 40(7):452-463. PubMed ID: 31147200
[TBL] [Abstract][Full Text] [Related]
34. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.
Chalmers JD; Tebboth A; Gayle A; Ternouth A; Ramscar N
NPJ Prim Care Respir Med; 2017 Jun; 27(1):43. PubMed ID: 28663549
[TBL] [Abstract][Full Text] [Related]
35. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
[TBL] [Abstract][Full Text] [Related]
36. Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis.
Oshagbemi OA; Odiba JO; Daniel A; Yunusa I
Curr Drug Targets; 2019; 20(16):1670-1679. PubMed ID: 31393244
[TBL] [Abstract][Full Text] [Related]
37. C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD.
Oshagbemi OA; Franssen FME; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Boer A; de Vries F
Pulm Pharmacol Ther; 2020 Feb; 60():101870. PubMed ID: 31785343
[TBL] [Abstract][Full Text] [Related]
38. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
39. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
Oshagbemi OA; Franssen FME; van Kraaij S; Braeken DCW; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Vries F
COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
[TBL] [Abstract][Full Text] [Related]
40. Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane?
Kaplan AG
J Am Board Fam Med; 2020; 33(2):289-302. PubMed ID: 32179613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]